Canopy Growth Corp Deferred Income Tax Expense (Benefit)
Canopy Growth Corp (CGC) reported Deferred Income Tax Expense (Benefit) of CAD 36.00 thousand for the 12-month period ending 2026-03-31, per its 10-K filed 2026-06-15.
Financial Statements › Cash Flow › Operating Activities
us-gaap:DeferredIncomeTaxExpenseBenefit · last filed 2026-06-15
- Canopy Growth Corp deferred income tax expense (benefit) for fiscal 2026 was 36.00K CAD, a 99.47% decline from fiscal 2025.
- Canopy Growth Corp deferred income tax expense (benefit) for fiscal 2025 was 6.80M CAD, a 43.59% decline from fiscal 2024.
- Canopy Growth Corp deferred income tax expense (benefit) for fiscal 2024 was 12.06M CAD.
- Canopy Growth Corp deferred income tax expense (benefit) for fiscal 2023 was -1.62M CAD.
| Period end | Deferred Income Tax Expense (Benefit) 12 month | Deferred Income Tax Expense (Benefit) 12 month as first filed |
|---|---|---|
| 2026-03-31 | 36.00K CAD 10-K · filed 2026-06-15 | |
| 2025-03-31 | 6.80M CAD 10-K · filed 2026-06-15 | |
| 2024-03-31 | 12.06M CAD 10-K · filed 2026-06-15 | |
| 2023-03-31 | -1.62M CAD 10-K · filed 2025-05-30 | -667.00K CAD 10-K · filed 2023-06-22 |
| 2022-03-31 | -6.58M CAD 10-K · filed 2024-05-30 | |
| 2021-03-31 | -34.55M CAD 10-K · filed 2023-06-22 | |
| 2020-03-31 | -138.31M CAD 10-K · filed 2022-05-31 | |
| 2019-03-31 | 1.72M CAD 10-K · filed 2021-06-01 | |
| 2018-03-31 | -392.00K CAD 10-K · filed 2020-06-01 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| USANA HEALTH SCIENCES INC (USNA) | United States | $0.264B | -17.90 |
| Niagen Bioscience, Inc. (NAGE) | United States | $0.238B | 15.72 |
| Tilray Brands, Inc. (TLRY) | United States | $0.554B | -5.97 |
| FITLIFE BRANDS, INC. (FTLF) | United States | $0.087B | 16.59 |
| MANNATECH INC (MTEX) | United States | $0.014B | |
| NATURAL ALTERNATIVES INTERNATIONAL INC (NAII) | United States | $0.011B | -1.16 |
| Synergy CHC Corp. (SNYR) | United States | $0.001B | |
| Functional Brands Inc. (MEHA) | United States | $0.001B | |
| Cronos Group Inc. (CRON) | $1.223B | ||
| Definium Therapeutics, Inc. (DFTX) | United States | $4.931B | -17.87 |